Company Overview
BGM Group Ltd operates within the healthcare sector, specifically focusing on the drug manufacturing industry for specialty and generic pharmaceuticals, where it functions as a manufacturer and distributor of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and various by-products produced in China. The company's portfolio includes specific licorice products such as Gan Di Xin, which serves as an antitussive and expectorant medicine, and Qilian Shan Licorice Extract, highlighting its specialization in niche therapeutic compounds. The firm employs a workforce of 298 individuals to support its manufacturing and distribution operations across the Chinese market. With a market capitalization of $94.25M and annual revenue of $29.87M, the company represents a small-cap entity within the pharmaceutical supply chain. These valuation and revenue figures indicate that BGM Group Ltd occupies a modest position in the broader healthcare landscape, reflecting the typical scale of specialized ingredient producers that serve larger pharmaceutical entities rather than competing directly in consumer-facing drug sales.
Financial Health
The company reported revenue of $29.87M over the trailing twelve months, yet it generated a net income of $-7,861,673 and an EBITDA of $-2,373,423, revealing a significant divergence between top-line generation and bottom-line profitability that points to a substantial cost structure burden. Despite the negative net income, the company maintains positive free cash flow of $3.36M, which suggests a degree of financial flexibility allowing for operational continuity despite accounting losses. The gross margin stands at 2.9%, indicating that the cost of goods sold consumes nearly all of the revenue before operating expenses are considered. Operating margins are further compressed to -5.4%, while the profit margin reaches -26.3%, demonstrating that overhead and general administrative expenses are eroding profitability at a rate significantly higher than the cost of production. On the balance sheet, the company holds $25.36M in cash against a debt load of $100,756, supported by a debt-to-equity ratio of 0.22, which characterizes the financial position as conservative and highly leveraged-free relative to its asset base. Liquidity is robust with a current ratio of 7.05, indicating that the company possesses ample current assets to cover short-term obligations without strain. Return on equity is recorded at -16.5% and return on assets at -3.8%, metrics that reveal management is currently unable to generate positive returns on the capital invested or the assets employed to run the business.
Valuation Assessment
Trailing P/E and forward P/E ratios are both listed as N/A due to the company's lack of positive earnings, implying that traditional earnings-based valuation models cannot be applied to determine future earnings trajectory. The price-to-book ratio is 0.25, which indicates that the market values the company at less than one-quarter of its book value, suggesting a significant discount or market skepticism regarding the recoverability of its assets. Alternative valuation metrics include a price-to-sales ratio of 3.16 and an EV/EBITDA of -29.15, suggesting that investors are pricing the stock based on sales potential or asset backing rather than cash flow generation or earnings power. The 52-week high is $17.17 and the 52-week low is $0.45, placing the current trading price in a context of extreme volatility within this specific range. The beta value is 1.46, meaning the stock price is expected to exhibit 46% more volatility than the broader market, reflecting high sensitivity to market fluctuations.
Growth & Income
Revenue growth year-over-year is -56.9%, while earnings growth is recorded at 0.0%, indicating that earnings are not growing faster than revenue and are actually contracting in the face of declining top-line sales. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that the firm retains all available cash flow for operational needs or reinvestment rather than distributing income to shareholders. Consequently, the company reinvests earnings, or in this case, cash flow, into growth initiatives or working capital requirements rather than paying dividends to investors. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, presenting a challenging environment for capital appreciation and income generation simultaneously.